News

Article

AJMC® in the Press, February 9, 2024

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Articles in Medriva and Becker’s Payer Issues referenced a study published in the February 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Screening for Health Literacy, Social Determinants, and Discrimination in Health Plans,” found that calling patients at the time of enrollment in a health plan could help in collecting health literacy data.

A piece by PharmExec referenced an article published by AJMC’s sister site, The Center for Biosimilars®. The article, “Why Pharmacovigilance Is Important for Biosimilars,” emphasized the need for constant pharmacovigilance among clinicians due to how many factors can affect the quality and performance of biosimilars.

Related Videos
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Tiara Green, MSEd
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 4 experts on PNH
Related Content
SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com
July 26th 2024

Potential Biomarkers Predict Disease Severity and Treatment Response in SMA

Kyle Munz
Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).
Managed Care Cast logo
July 25th 2024

Dr Jason Spangler on Enhancing Equity in Health Technology Assessment

Brooke McCormick
On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.
FDA approval stamp. | Image Credit: Surendra - stock.adobe.com
July 26th 2024

FDA Approves Deuruxolitinib for Alopecia Areata

Cameron Santoro
The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.
Managed Care Cast: Frameworks for Advancing Health Equity
July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi
Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com
July 26th 2024

AI Model Precisely Identifies HCC Recurrence Risk Factors

Rose McNulty
Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.
Red blood drop with double helix | Image credit: Елена Бутусова-stock.adobe.com
July 26th 2024

Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial

Laura Joszt, MA
The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo